Study of a myo-inositol hexaphosphate-based cream to prevent dystrophic calcinosis cutis

Br J Dermatol. 2005 May;152(5):1022-5. doi: 10.1111/j.1365-2133.2005.06382.x.

Abstract

Background: Calcinosis cutis is a disorder caused by abnormal deposits of calcium phosphate in the skin and is observed in diverse disorders. Myo-inositol hexaphosphate (InsP(6)) is a diet-dependent molecule found in all mammalian fluids and tissues, which exhibits an extraordinary capacity as a crystallization inhibitor of calcium salts.

Objectives: To establish the effects of topically administered InsP(6) cream on artificially provoked dystrophic calcifications in soft tissues.

Methods: Fourteen male Wistar rats were randomly assigned into two groups: control and treated groups. Rats were fed with an InsP(6)-free or phytate diet. Plaque formation was induced by subcutaneous injection of 0.1% KMnO(4) solution. From 4 days before plaque induction to the end of the experiment, control rats were treated topically with a standard cream, whereas treated rats were treated with the same cream with 2% InsP(6) or phytate (as sodium salt). Calcification of plaques was allowed to proceed for 10 days. InsP(6) in urine was determined. The plaques were excised and weighed.

Results: It was found that when InsP(6) was administered topically through a moisturizing cream (2% InsP(6)-rich), the plaque size and weight were notably and significantly reduced compared with the control group (1.6 +/- 1.1 mg InsP(6)-treated, 26.7 +/- 3.0 mg control). The InsP(6) urinary levels for animals treated with the InsP(6)-enriched cream were considerably and significantly higher than those found in animals treated topically with the cream without InsP(6) (16.96 +/- 4.32 mg L(-1) InsP(6)-treated, 0.06 +/- 0.03 mg L(-1) control).

Conclusions: This demonstrates the important capacity of InsP(6) as a crystallization inhibitor and also demonstrates that it is possible to propose topical use as a new InsP(6) administration route.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Cutaneous
  • Animals
  • Calcinosis / chemically induced
  • Calcinosis / pathology
  • Calcinosis / prevention & control*
  • Male
  • Ointments
  • Phytic Acid / therapeutic use*
  • Phytic Acid / urine
  • Potassium Permanganate
  • Rats
  • Rats, Wistar
  • Skin Diseases / chemically induced
  • Skin Diseases / pathology
  • Skin Diseases / prevention & control*

Substances

  • Ointments
  • Potassium Permanganate
  • Phytic Acid